Skip to main content
PMC home page
Journal of Epidemiology and Community Health logoLink to Journal of Epidemiology and Community Health
. 2005 Nov;59(11):927–933. doi: 10.1136/jech.2005.034900

Cost effectiveness of statins in coronary heart disease

O Franco 1, A Peeters 1, C Looman 1, L Bonneux 1
PMCID: PMC1732951  PMID: 16234419

Abstract

Introduction: Statin therapy reduces the rate of coronary heart disease, but high costs in combination with a large population eligible for treatment ask for priority setting. Although trials agree on the size of the benefit, economic analyses of statins report contradictory results. This article reviewed cost effectiveness analyses of statins and sought to synthesise cost effectiveness ratios for categories of risk of coronary heart disease and age.

Methods: The review searched for studies comparing statins with no treatment for the prevention of either cardiovascular or coronary heart disease in men and presenting cost per years of life saved as outcome. Estimates were extracted, standardised for calendar year and currency, and stratified by categories of risk, age, and funding source

Results: 24 studies were included (from 50 retrieved), yielding 216 cost effectiveness ratios. Estimated ratios increase with decreasing risk. After stratification by risk, heterogeneity of ratios is large varying from savings to $59 000 per life year saved in the highest risk category and from $6500 to $490 000 in the lowest category. The pooled estimates show values of $21571 per life year saved for a 10 year coronary heart disease risk of 20% and $16862 per life year saved for 10 year risk of 30%.

Conclusion: Statin therapy is cost effective for high levels of risk, but inconsistencies exist at lower levels. Although the cost effectiveness of statins depends mainly on absolute risk, important heterogeneity remains after adjusting for absolute risk. Economic analyses need to increase their transparency to reduce their vulnerability to bias and increase their reproducibility.

Full Text

The Full Text of this article is available as a PDF (90.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashraf T., Hay J. W., Pitt B., Wittels E., Crouse J., Davidson M., Furberg C. D., Radican L. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996 Aug 15;78(4):409–414. doi: 10.1016/s0002-9149(96)00328-1. [DOI] [PubMed] [Google Scholar]
  2. Assmann G., Schulte H. Primary prevention of coronary heart disease in the Federal Republic of Germany. Analysis of cost-effectiveness. Drugs. 1990;40 (Suppl 1):33–37. doi: 10.2165/00003495-199000401-00008. [DOI] [PubMed] [Google Scholar]
  3. Attanasio E., Russo P., Allen S. E. Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease. Clin Ther. 2001 Feb;23(2):276–275. doi: 10.1016/s0149-2918(01)80010-2. [DOI] [PubMed] [Google Scholar]
  4. Caro J., Klittich W., McGuire A., Ford I., Norrie J., Pettitt D., McMurray J., Shepherd J. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ. 1997 Dec 13;315(7122):1577–1582. doi: 10.1136/bmj.315.7122.1577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chau J., Cheung B. M., McGhee S. M., Lauder I. J., Lau C. P., Kumana C. R. Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong. Hong Kong Med J. 2001 Dec;7(4):360–368. [PubMed] [Google Scholar]
  6. Cobos A., Jovell A. J., García-Altés A., García-Closas R., Serra-Majem L. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis. Clin Ther. 1999 Nov;21(11):1924–1936. doi: 10.1016/S0149-2918(00)86740-5. [DOI] [PubMed] [Google Scholar]
  7. Creese A. Global trends in health care reform. World Health Forum. 1994;15(4):317–322. [PubMed] [Google Scholar]
  8. Cucherat M., Boissel J. P. A mathematical model for the determination of the optimum value of the treatment threshold for a continuous risk factor. Eur J Epidemiol. 1998 Jan;14(1):23–29. doi: 10.1023/a:1007423730270. [DOI] [PubMed] [Google Scholar]
  9. D'Agostino R. B., Sr, Grundy S., Sullivan L. M., Wilson P., CHD Risk Prediction Group Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001 Jul 11;286(2):180–187. doi: 10.1001/jama.286.2.180. [DOI] [PubMed] [Google Scholar]
  10. Drummond M., Brandt A., Luce B., Rovira J. Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential. Int J Technol Assess Health Care. 1993 Winter;9(1):26–36. doi: 10.1017/s0266462300003007. [DOI] [PubMed] [Google Scholar]
  11. Elliott W. J., Weir D. R. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am J Health Syst Pharm. 1999 Sep 1;56(17):1726–1732. doi: 10.1093/ajhp/56.17.1726. [DOI] [PubMed] [Google Scholar]
  12. Field K., Thorogood M., Silagy C., Normand C., O'Neill C., Muir J. Strategies for reducing coronary risk factors in primary care: which is most cost effective? BMJ. 1995 Apr 29;310(6987):1109–1112. doi: 10.1136/bmj.310.6987.1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ganz D. A., Kuntz K. M., Jacobson G. A., Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med. 2000 May 16;132(10):780–787. doi: 10.7326/0003-4819-132-10-200005160-00003. [DOI] [PubMed] [Google Scholar]
  14. Goldman L. Cost-effectiveness perspectives in coronary heart disease. Am Heart J. 1990 Mar;119(3 Pt 2):733–740. doi: 10.1016/s0002-8703(05)80054-7. [DOI] [PubMed] [Google Scholar]
  15. Goldman L., Weinstein M. C., Goldman P. A., Williams L. W. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991 Mar 6;265(9):1145–1151. [PubMed] [Google Scholar]
  16. Grover S. A., Coupal L., Paquet S., Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med. 1999 Mar 22;159(6):593–600. doi: 10.1001/archinte.159.6.593. [DOI] [PubMed] [Google Scholar]
  17. Grover S. A., Coupal L., Zowall H., Alexander C. M., Weiss T. W., Gomes D. R. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care. 2001 Jan;24(1):45–50. doi: 10.2337/diacare.24.1.45. [DOI] [PubMed] [Google Scholar]
  18. Grover S. A., Coupal L., Zowall H., Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated? Circulation. 2000 Aug 15;102(7):722–727. doi: 10.1161/01.cir.102.7.722. [DOI] [PubMed] [Google Scholar]
  19. Hamilton V. H., Racicot F. E., Zowall H., Coupal L., Grover S. A. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. JAMA. 1995 Apr 5;273(13):1032–1038. [PubMed] [Google Scholar]
  20. Hay J. W., Wittels E. H., Gotto A. M., Jr An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol. 1991 Apr 15;67(9):789–796. doi: 10.1016/0002-9149(91)90609-o. [DOI] [PubMed] [Google Scholar]
  21. Hay J. W., Yu W. M., Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics. 1999 Jan;15(1):47–74. doi: 10.2165/00019053-199915010-00004. [DOI] [PubMed] [Google Scholar]
  22. Huse D. M., Russell M. W., Miller J. D., Kraemer D. F., D'Agostino R. B., Ellison R. C., Hartz S. C. Cost-effectiveness of statins. Am J Cardiol. 1998 Dec 1;82(11):1357–1363. doi: 10.1016/s0002-9149(98)00641-9. [DOI] [PubMed] [Google Scholar]
  23. Jacobson T. A. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. Am J Cardiol. 1996 Sep 26;78(6A):32–41. doi: 10.1016/s0002-9149(96)00660-1. [DOI] [PubMed] [Google Scholar]
  24. Jacobson T. A., Schein J. R., Williamson A., Ballantyne C. M. Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med. 1998 Oct 12;158(18):1977–1989. doi: 10.1001/archinte.158.18.1977. [DOI] [PubMed] [Google Scholar]
  25. Johannesson M., Jönsson B., Kjekshus J., Olsson A. G., Pedersen T. R., Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997 Jan 30;336(5):332–336. doi: 10.1056/NEJM199701303360503. [DOI] [PubMed] [Google Scholar]
  26. Jönsson B., Cook J. R., Pedersen T. R. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia. 1999 Nov;42(11):1293–1301. doi: 10.1007/s001250051441. [DOI] [PubMed] [Google Scholar]
  27. Jönsson B., Johannesson M., Kjekshus J., Olsson A. G., Pedersen T. R., Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) Eur Heart J. 1996 Jul;17(7):1001–1007. doi: 10.1093/oxfordjournals.eurheartj.a014994. [DOI] [PubMed] [Google Scholar]
  28. Knopp R. H. Drug treatment of lipid disorders. N Engl J Med. 1999 Aug 12;341(7):498–511. doi: 10.1056/NEJM199908123410707. [DOI] [PubMed] [Google Scholar]
  29. LaRosa J. C., He J., Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999 Dec 22;282(24):2340–2346. doi: 10.1001/jama.282.24.2340. [DOI] [PubMed] [Google Scholar]
  30. Laupacis A., Feeny D., Detsky A. S., Tugwell P. X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992 Feb 15;146(4):473–481. [PMC free article] [PubMed] [Google Scholar]
  31. Law M. R., Wald N. J., Rudnicka A. R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003 Jun 28;326(7404):1423–1423. doi: 10.1136/bmj.326.7404.1423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Lim S. S., Vos T., Peeters A., Liew D., McNeil J. J. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria. Med J Aust. 2001 Nov 5;175(9):459–464. doi: 10.5694/j.1326-5377.2001.tb143676.x. [DOI] [PubMed] [Google Scholar]
  33. Martens L. L., Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther. 1994 Nov-Dec;16(6):1052–1036. [PubMed] [Google Scholar]
  34. McKenney J. M., Kinosian B. Economic benefits of aggressive lipid lowering: a managed care perspective. Am J Manag Care. 1998 Jan;4(1):65–74. [PubMed] [Google Scholar]
  35. Morris S. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Econ. 1997 Nov-Dec;6(6):589–601. doi: 10.1002/(sici)1099-1050(199711)6:6<589::aid-hec286>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  36. Muls E., Van Ganse E., Closon M. C. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis. 1998 Apr;137 (Suppl):S111–S116. doi: 10.1016/s0021-9150(97)00321-3. [DOI] [PubMed] [Google Scholar]
  37. Perreault S., Hamilton V. H., Lavoie F., Grover S. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther. 1997 Jan;10(6):787–794. doi: 10.1007/BF00053037. [DOI] [PubMed] [Google Scholar]
  38. Perreault S., Hamilton V. H., Lavoie F., Grover S. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective? Arch Intern Med. 1998 Feb 23;158(4):375–381. doi: 10.1001/archinte.158.4.375. [DOI] [PubMed] [Google Scholar]
  39. Perreault S., Levinton C., Le Lorier J. Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia. Can J Clin Pharmacol. 2000 Autumn;7(3):144–154. [PubMed] [Google Scholar]
  40. Pharoah P. D., Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ. 1996 Jun 8;312(7044):1443–1448. doi: 10.1136/bmj.312.7044.1443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Pickin D. M., McCabe C. J., Ramsay L. E., Payne N., Haq I. U., Yeo W. W., Jackson P. R. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart. 1999 Sep;82(3):325–332. doi: 10.1136/hrt.82.3.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Plans Rubió P., Rovira Forns J. Estudio coste-efectividad de los tratamientos farmacológicos hipolipemiantes. Med Clin (Barc) 1995 Sep 23;105(9):327–333. [PubMed] [Google Scholar]
  43. Prosser L. A., Stinnett A. A., Goldman P. A., Williams L. W., Hunink M. G., Goldman L., Weinstein M. C. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med. 2000 May 16;132(10):769–779. doi: 10.7326/0003-4819-132-10-200005160-00002. [DOI] [PubMed] [Google Scholar]
  44. Raithatha Nick, Smith Richard D. Paying for statins. BMJ. 2004 Feb 14;328(7436):400–402. doi: 10.1136/bmj.328.7436.400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Redaelli Alberto, Cranor Carole W., Okano Gary J., Reese Pat Ray. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics. 2003;21(17):1213–1238. doi: 10.2165/00019053-200321170-00001. [DOI] [PubMed] [Google Scholar]
  46. Rivière M., Wang S., Leclerc C., Fitzsimon C., Tretiak R. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. CMAJ. 1997 Apr 1;156(7):991–997. [PMC free article] [PubMed] [Google Scholar]
  47. Russell M. W., Huse D. M., Miller J. D., Kraemer D. F., Hartz S. C. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol. 2001 Spring;8(1):9–16. [PubMed] [Google Scholar]
  48. Schulman K. A., Kinosian B., Jacobson T. A., Glick H., Willian M. K., Koffer H., Eisenberg J. M. Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA. 1990 Dec 19;264(23):3025–3033. [PubMed] [Google Scholar]
  49. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
  50. Smart A. J., Walters L. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors. S Afr Med J. 1994 Dec;84(12):834–837. [PubMed] [Google Scholar]
  51. Spearman M. E., Summers K., Moore V., Jacqmin R., Smith G., Groshen S. Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization. Clin Ther. 1997 May-Jun;19(3):582–539. doi: 10.1016/s0149-2918(97)80142-7. [DOI] [PubMed] [Google Scholar]
  52. Szucs T. D., Berger K., März W., Schäfer J. R. Kosteneffektivität von Pravastatin in der koronaren Sekundärprävention bei Patienten mit Myokardinfarkt oder instabiler Angina pectoris in Deutschland. Eine Analyse auf der Grundlage der LIPID-Studie. Herz. 2000 Aug;25(5):487–494. doi: 10.1007/pl00001961. [DOI] [PubMed] [Google Scholar]
  53. Szucs T. D., Guggenberger G., Berger K., März W., Schäfer J. R. Pharmakoökonomische Bewertung von Pravastatin in der Sekundärprävention der koronaren Herzkrankheit bei Patienten mit durchschnittlichen Cholesterinwerten. Eine Analyse für Deutschland auf der Grundlage der CARE-Studie. Herz. 1998 Aug;23(5):319–329. doi: 10.1007/BF03044365. [DOI] [PubMed] [Google Scholar]
  54. Tengs T. O., Adams M. E., Pliskin J. S., Safran D. G., Siegel J. E., Weinstein M. C., Graham J. D. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995 Jun;15(3):369–390. doi: 10.1111/j.1539-6924.1995.tb00330.x. [DOI] [PubMed] [Google Scholar]
  55. Thompson D., Oster G. Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature. Pharmacoeconomics. 1992 Jul;2(1):34–42. doi: 10.2165/00019053-199202010-00005. [DOI] [PubMed] [Google Scholar]
  56. Troche C. J., Tacke J., Hinzpeter B., Danner M., Lauterbach K. W. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur Heart J. 1998 Apr;19 (Suppl 100):C59–C65. [PubMed] [Google Scholar]
  57. Tsevat J., Kuntz K. M., Orav E. J., Weinstein M. C., Sacks F. M., Goldman L. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J. 2001 May;141(5):727–734. doi: 10.1067/mhj.2001.114805. [DOI] [PubMed] [Google Scholar]
  58. Tárraga López P. J., Celada Rodríguez A., Cerdán Oliver M., Solera Albero J., Ocaña López J. M., de Miguel Clavé J. Análisis coste-efectividad de atorvastatina frente a simvastatina como tratamiento hipolipemiante en pacientes hipercolesterolémicos en atención primaria. Aten Primaria. 2001 Jan;27(1):18–24. doi: 10.1016/S0212-6567(01)78767-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Wei Li, Ebrahim Shah, Bartlett Christopher, Davey Peter D., Sullivan Frank M., MacDonald Thomas M. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ. 2005 Mar 24;330(7495):821–821. doi: 10.1136/bmj.38398.408032.8F. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Wendland G., Klever-Deichert G., Lauterbach K. Kosteneffektivität der lipidsenkenden Therapie. Herz. 2001 Dec;26(8):552–560. doi: 10.1007/pl00002059. [DOI] [PubMed] [Google Scholar]
  61. van Hout B. A., Simoons M. L. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J. 2001 May;22(9):751–761. doi: 10.1053/euhj.2000.2308. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Publishing Group

RESOURCES